{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:28:52Z","timestamp":1794216532411,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["21JR11RA191"],"award-info":[{"award-number":["21JR11RA191"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jneuroim.2026.579076","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:11:29Z","timestamp":1788221489000},"page":"579076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CASPR2 antibody-associated neurological syndrome after PD-1 inhibitor treatment (tislelizumab) in a patient with lung adenocarcinoma: A case report and literature review"],"prefix":"10.1016","volume":"421","author":[{"given":"Lingfang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhuan","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jneuroim.2026.579076_bb0005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/jnnp-2011-301506","article-title":"Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia","volume":"83","author":"Becker","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579076_bb0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ene.13180","article-title":"Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome","volume":"24","author":"Bien","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579076_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.579076_bb0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1474-4422(23)00083-2","article-title":"Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease","volume":"22","author":"Dalmau","year":"2023","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579076_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2026.579076_bb0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jneuroim.2026.579076_bb0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579076_bb0040","article-title":"Thymoma and autoimmune encephalitis: clinical manifestations and antibodies","volume":"8","author":"Guasp","year":"2021","journal-title":"Neurol.(R) Neuroimmunol. Neuroinflamm."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2026.579076_bb0045","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.4103\/AMJM.AMJM_59_24","article-title":"Tislelizumab: redefining PD-1 targeting strategies in the era of precision oncology","volume":"20","author":"Lakshmi","year":"2024","journal-title":"Amrita J. Med."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579076_bb0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13052-024-01727-5","article-title":"Clinical characteristics and long-term outcome of CASPR2 antibody-associated autoimmune encephalitis in children","volume":"50","author":"Liao","year":"2024","journal-title":"Ital. J. Pediatr."},{"issue":"11","key":"10.1016\/j.jneuroim.2026.579076_bb0055","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook","volume":"8","author":"M\u00f6hn","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jneuroim.2026.579076_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1108116","article-title":"Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events","volume":"14","author":"M\u00fcller-Jensen","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.jneuroim.2026.579076_bb0065","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/jnnp-2020-323226","article-title":"Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features","volume":"91","author":"Mu\u00f1iz-Castrillo","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jneuroim.2026.579076_bb0070","first-page":"173","article-title":"Tislelizumab: structural innovations and expanding clinical horizons in next-generation PD-1 immunotherapy","volume":"11","author":"Nguyen","year":"2025","journal-title":"Chronic Dis. Transl. Med."},{"key":"10.1016\/j.jneuroim.2026.579076_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.736035","article-title":"Clinical features and outcomes in Pediatric autoimmune encephalitis associated with CASPR2 antibody","volume":"9","author":"Tan","year":"2021","journal-title":"Front. Pediatr."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.579076_bb0080","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2026.579076_bb0085","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s10072-022-06560-4","article-title":"Anti-CASPR2 encephalitis in a liver posttransplant patient receiving immune-suppression and lenvatinib: a case report and literature review","volume":"44","author":"Wang","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2026.579076_bb0090","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control: J. Moffitt Cancer Cent."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.579076_bb0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00415-025-12992-7","article-title":"Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review","volume":"272","author":"Zhang","year":"2025","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.579076_bb0100","article-title":"Comprehensive analysis of paraneoplastic neurologic syndrome and PNS-CARE diagnostic criteria in clinical practice","volume":"11","author":"Zhao-Fleming","year":"2024","journal-title":"Neurol.(R) Neuroimmunol. Neuroinflamm."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826002250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826002250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:18:33Z","timestamp":1794215913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826002250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":20,"alternative-id":["S0165572826002250"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579076","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CASPR2 antibody-associated neurological syndrome after PD-1 inhibitor treatment (tislelizumab) in a patient with lung adenocarcinoma: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"579076"}}